Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.32 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708617 | 0.92 | PARP14 (0.41) | PARP14DRD2DRD4DRD3LMNA | |
| SCHEMBL6711435 | 0.90 | PARP14 (0.42) | PARP14PRSS12MEN1KMT2ALMNA | |
| SCHEMBL6712091 | 0.90 | PARP14 (0.39) | PARP14MAP3K5MEN1KMT2ALMNA | |
| SCHEMBL6710524 | 0.90 | PLCG2 (0.38) | PARP14MAP3K5LMNATP53POLB | |
| SCHEMBL6707786 | 0.90 | GALR3 (0.36) | PARP14MEN1KMT2ALMNAPOLB | |
| SCHEMBL6707760 | 0.89 | PARP14 (0.41) | PARP14MEN1KMT2ALMNAPOLB | |
| SCHEMBL6711927 | 0.89 | PARP14 (0.44) | PARP14LMNATP53POLBMAPT | |
| SCHEMBL6712039 | 0.89 | MAP3K5 (0.40) | DRD2DRD4DRD3MAP3K5PRSS12 | |
| SCHEMBL6707817 | 0.88 | GPR35 (0.35) | PARP14MAP3K5MEN1KMT2ALMNA | |
| SCHEMBL6709018 | 0.88 | PKM (0.35) | PARP14MAP3K5LMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | PARP14 2597/4885DRD2 1672/4885DRD4 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.